A Physician Breaks Down What Peptides Actually Do and Where the Science Stands
Dr. Abud Bakri covers BPC-157, epithalon, GHK-Cu, GLP-1s, and growth hormone peptides โ separating real evidence from hype.
28 articles
Dr. Abud Bakri covers BPC-157, epithalon, GHK-Cu, GLP-1s, and growth hormone peptides โ separating real evidence from hype.
A comprehensive review reveals BPC-157 lacks validated formulations, human PK data, and a coherent drug development path despite 30+ years of preclinical research.
PepMimic uses binding interface mimicry to convert antibodies or receptors into short peptides, achieving nanomolar affinity against major cancer targets.
A comprehensive review reveals BPC-157's clinical translation is blocked not by lack of biological activity, but by absent pharmaceutical development.
A new AI pipeline named HelixFold-Multistate designs peptides that selectively activate or block key drug-target receptors with nanomolar potency.
Comprehensive review examines peptide therapeutics targeting aging hallmarks, from FDA-approved drugs to experimental compounds.
Comprehensive review reveals cutting-edge techniques for analyzing protein drugs, improving development and therapeutic outcomes.
The FDA will convene advisory panels in July 2025 to reconsider whether compounding pharmacies can legally produce certain popular peptides removed from approved lists in 2023.
Icotrokinra, a breakthrough oral peptide targeting IL-23, demonstrates significant skin clearance in psoriasis with sustained benefits through 52 weeks.
Bryan Johnson offers guidance on peptides โ what they are, how they work, and what health-optimizers should consider before using them.
A board-certified physician breaks down BPC-157, epithalon, GLP-1s, and growth hormone peptides โ separating real science from hype.
A new review maps approved vs. gray-market peptides in sports medicine, flagging scarce human safety data behind widely marketed compounds.